# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recen...
Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter...
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medi...
Pfizer launched a $1.5 billion cost reduction program to enhance operational efficiencies and cut costs amid declining sales. S...
The company disclosed the new program in a filing with the Securities and Exchange Commission.